Abstracts

433 – Cytoplasmic Tail Engineering of Stabilized mRNA Env Immunogens Enhances Neutralizing Response

Background Certain Env features, such as low cell surface expression and conformational lability, have hampered mRNA vaccine development for HIV. We previously found that ablation of Env endocytosis motifs and incorporation of a truncated HIV/SIV chimeric cytoplasmic tail (SIV.CT) increased surface expression on virions and cells transduced with vaccinia-vectored immunogens. Here, we incorporated this SIV.CT…

446 – HLA-E Prevents Natural Killer Cell Inhibition of HIV-1 Replication in Peripheral Blood CD4+ T Cells

Background The HIV-1 Nef has been shown to alter MHC-1 presentation on infected T cells, and infection of cell lines suggest upregulation of non-canonical HLA-E may be advantageous for Natural Killer (NK) cell evasion. Conflicting clinical reports leave the role of NK cells in infection control unclear. True mechanistic understanding of HIV replication and control…

409 – Impact of Gender-Affirming Hormone Therapy on T-Cell Phenotypes in Transgender Women With HIV

Background Understanding the impact of gender-affirming hormone therapy (GAHT) on immune regulation in transgender women living with HIV (TWH) is essential for improving HIV care and developing cure strategies. Methods TWH on suppressive ART initiating estradiol-based GAHT were recruited from HIV clinics in San Diego, CA, and Houston, TX. Blood samples were collected before and…

413 – Provirus From Early-Treated HIV Reveals Earlier Variants Targeted by Initial Neutralizing Antibodies

Background Antiretroviral therapy initiation (ARTi) halts HIV-1 replication but cannot clear persistent reservoirs. ARTi during acute (within 60 days of acquisition) and early (between ~60 and 120 days) HIV-1 limits reservoir size and diversity and can preserve nascent autologous neutralizing antibody (anAb) responses that target the transmitted/founder (TF) virus and then gain potency and breadth…

427 – Augmenting HIV-Specific CAR-T Cell Functionality by Treatment With Novel Cytokine-Based Scaffold

Background We previously described a bispecific CAR-T cell targeting two conserved gp120 epitopes (duoCAR-Ts) with potent anti-HIV activity, now in clinical trials. However, despite ART, many people living with HIV (PLWH) develop systemic inflammation associated with increased levels of TGF-β which may suppress the activity of infused duoCAR-Ts. We hypothesized that inhibiting TGF-β activity may…

434 – Improved Immunogenicity of a VLP-Forming mRNA Vaccine for HIV-1

Background The HIV-1 envelope (Env) is the sole target of broadly neutralizing antibodies and, therefore, the context in which it is presented to the immune system is critical for efficiently engaging responder B cells. We previously designed and tested in pre-clinical models a virus-like particle (VLP)-forming env-gag mRNA vaccine that elicited tier-2 neutralizing antibodies and…